MBX Biosciences (MBX) Change in Cash (2023 - 2026)

MBX Biosciences has reported Change in Cash for 4 years, with the latest figure at -$29.9 million in Q1 2026.

• Quarterly Change in Cash fell 53.59% year-over-year to -$29.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.5 million (up 380.99% YoY) and the FY2025 annual result came in at $25.9 million, up 37.76% from the prior year.
• Change in Cash improved to -$29.9 million in Q1 2026 per MBX's latest filing, from -$147.8 million in the prior quarter.
• Over five years, Change in Cash peaked at $183.3 million in Q3 2025 and troughed at -$147.8 million in Q4 2025.
• A 4-year average of -$2.5 million and a median of -$21.2 million in 2024 frame the typical range for Change in Cash.
• The widest YoY moves for Change in Cash: up 143.09% in 2025, down 496.74% in 2025.
• Over 4 years, Change in Cash stood at -$40.1 million in 2023, then sank by 108.36% to -$83.5 million in 2024, then tumbled by 77.02% to -$147.8 million in 2025, then jumped by 79.8% to -$29.9 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$29.9 million, -$147.8 million, and $183.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.